CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 15 enrolled
Drug / intervention
Dexmedetomidine +1 moredrug
Likely dose
Oral dexmedetomidineAI-extracted
Key inclusion· 4
  • ✓Age 18-50 years
  • ✓Native English speaking
  • ✓ASA physical status P1 or P2 (healthy or with stable chronic condition)
  • ✓Normal body habitus
Key exclusion· 7
  • ✕Abnormal sleep habits
  • ✕Sleep duration <5 hours per night
  • ✕Sleep onset before 9:00 PM or after 2:00 AM regularly
  • ✕Wake time before 5:00 AM or after 10:00 AM regularly

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02818569
NCT02818569Phase 2Completed
CompareCT.gov

Repurposing Dexmedetomidine as an Orally Administered Sleep Therapeutic

Massachusetts General Hospital·interventional·Posted Jun 29, 2016·Updated Oct 2, 2019

In Brief

A Phase 2 clinical trial evaluating Dexmedetomidine and Saline Placebo for Sleep and Insomnia. Completed, enrolled 15 participants across 1 site.

Detailed Summary

The broad objective of this investigation is to assess the safety and efficacy of oral therapy with dexmedetomidine for the induction and maintenance of restful sleep.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSleep, Insomnia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 29, 2016
Enrollment StartOct 1, 2016
Primary CompletionJun 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 10.0 years ago

Interventions

Dexmedetomidinedrug

Oral form

Saline Placeboother

Saline Placebo